Whole-exome sequencing and gene-based rare variant association tests suggest that PLA2G4E might be a risk gene for panic disorder

Yoshiro Morimoto1,2, Mihoko Shimada-Sugimoto3, Takeshi Otowa4, Shintaro Yoshida2, Akira Kinoshita2, Hiroyuki Mishima2, Naohiro Yamaguchi1, Takatoshi Mori5, Akira Imamura1, Hiroki Ozawa1, Naohiro Kurotaki1, Christiane Ziegler6,7, Katharina Domschke5,7, Jürgen Deckert6, Tadashi Umekage8, Mamoru Tochigi9, Hisanobu Kaiya10, Yuji Okazaki11, Katsushi Tokunaga3, Tsukasa Sasaki12, Koh-ichiro Yoshiura2 and Shinji Ono1,2,13

Abstract
Panic disorder (PD) is characterized by recurrent and unexpected panic attacks, subsequent anticipatory anxiety, and phobic avoidance. Recent epidemiological and genetic studies have revealed that genetic factors contribute to the pathogenesis of PD. We performed whole-exome sequencing on one Japanese family, including multiple patients with panic disorder, which identified seven rare protein-altering variants. We then screened these genes in a Japanese PD case–control group (384 sporadic PD patients and 571 controls), resulting in the detection of three novel single nucleotide variants as potential candidates for PD (chr15: 42631993, T>C in GANC; chr15: 42342861, G>T in PLA2G4E; chr20: 3641457, G>C in GFRA4). Statistical analyses of these three genes showed that PLA2G4E yielded the lowest p value in gene-based rare variant association tests by Efficient and Parallelizable Association Container Toolbox algorithms; however, the p value did not reach the significance threshold in the Japanese. Likewise, in a German case–control study (96 sporadic PD patients and 96 controls), PLA2G4E showed the lowest p value but again did not reach the significance threshold. In conclusion, we failed to find any significant variants or genes responsible for the development of PD. Nonetheless, our results still leave open the possibility that rare protein-altering variants in PLA2G4E contribute to the risk of PD, considering the function of this gene.

Introduction
Panic disorder (PD) is characterized by recurrent and unexpected panic attacks, subsequent anticipatory anxiety, and phobic avoidance. The lifetime prevalence of PD is 4.7%, with a female preponderance1. Several genetic and epidemiological studies, including family and twin studies, have shown that genetic factors play an important role in the pathogenesis of PD. First-degree relatives of patients with PD have a sixfold greater risk for developing this disease2, and twin studies have shown a higher concordance rate in monozygotic twins than in dizygotic ones3. Neurodevelopmental disorders, including PD, are basically considered as multifactorial diseases. Thus far, several genome-wide association studies (GWAS) using DNA microarrays have focused on PD, but they have not been consistently replicated elsewhere4–6. Whole-exome sequencing (WES) is a powerful tool to detect genes causative of not only single-gene disorders, but also
multifactorial ones, including autism spectrum disorder. Regarding PD, to the best of our knowledge, only a few studies have explored genes causative of this condition using next-generation sequencing (NGS).

To identify genes related to PD, we performed WES in a Japanese family including several members with PD and identified variants linked to this disorder in this family. After identifying the genes that were candidates for causing PD in this family, the frequencies of all variants of these genes were compared between larger groups of PD cases and controls not related to this family. Here, we describe the results of NGS and the assessment of rare protein-altering variants of potential candidate genes in patients with PD and ethnically matched controls.

**Subjects and methods**

**Clinical presentation of a Japanese family including multiple PD patients**

The proband (II-12) was a 40-year-old woman (Fig. 1). She had consulted a psychiatric clinic because of panic attacks and anticipatory anxiety. Her mother and elder sister (I-12 and II-1, respectively) had also consulted a psychiatric hospital because of symptoms similar to those in the proband. All of these three (I-12, II-1, and II-12) had been diagnosed with panic disorder by their attending psychiatrists. Among all affected individuals, three out of six (II-6, III-3, and III-4) had also consulted at a psychiatric hospital because of panic attacks and anticipatory anxiety and been diagnosed with panic disorder, as well as having incongruity of emotional responses, social withdrawal, and lethargy-like negative symptoms of schizophrenia. However, they did not fulfill the criteria for schizophrenia. All affected members in this family have similar panic symptoms in common, including panic attacks and anticipatory anxiety. We considered all of them as being “affected” and estimated that they have a shared disease-causing variant, and thus subjected them to further genetic analysis. Sertraline was effective for the treatment of their panic symptoms in many of the affected individuals. All subjects in this family were evaluated by multiple psychiatrists using the MINI International Neuropsychiatric Interview. All diagnoses of psychiatric diseases were made in accordance with the International Classification of Diseases, revision 10 (ICD-10), and the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). The father of the proband was the second eldest of ten siblings, who had not been suffering from any psychiatric diseases. The eldest sister and brother of the proband (II-1 and II-2, respectively) had never married and had no children. The second eldest sister and brother (II-4 and II-7) and their children (III-1, III-5, and III-6) had also not been suffering from any psychiatric diseases. Detailed information about them is summarized in Fig. 1 and Supplementary Table 1.

**Analysis of the mode of inheritance in this family using the SAGE program**

To explore the mode of inheritance in this family, we performed complex segregation analysis using Statistical Analysis for Genetic Epidemiology, Release 6.4 (SAGE) [http://darwin.cwru.edu/sage/]. Four of the family members (III-7, III-8, III-9, and III-10) were excluded from this analysis since they had not reached the mean age of the
onset of PD (24 years old). We considered four different inheritance models: (a) sporadic model without familial residual association; (b) sporadic model with familial residual association; (c) Mendelian major gene models with autosomal-dominant inheritance; and (d) Mendelian major gene models with autosomal recessive inheritance. Akaike’s Information Criterion (AIC) was used to estimate the best fitting model among these four alternatives.

**Japanese and German PD case–control groups**
A total of 669 sporadic PD cases and 859 control samples were collected from two countries, Japan and Germany (952 Japanese and 576 German). All of these patients with PD had been diagnosed by psychiatrists in accordance with ICD-10, DSM-III, or DSM-IV. Their details are summarized in Supplementary Table 2. All participants provided informed consent to undergo genetic research, which was approved by the ethics committees.

**DNA extraction**
We recruited nine members of this family for this study, namely, five affected and four unaffected individuals (Fig. 1). Genomic DNA was extracted from peripheral blood leukocytes using a QIAamp DNA Midi kit (QIAGEN, Hilden, Germany).

**Whole-exome sequencing**
We assessed DNA quality using NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA) and Qbit Fluorometer Nucleic Acid Quantification (QIAGEN, Hilden, Germany) and selected four high-quality DNA samples (I-2, I-12, II-10, and II-12) for WES. We performed WES on two affected individuals with PD and two unaffected individuals in this family (Fig. 1), using Agilent SureSelect Exome Target Enrichment System v5 (Agilent Technologies, Santa Clara, CA, USA), followed by paired-end sequencing on SOLiD 5500xl sequencers (Life Technologies, Carlsbad, CA, USA). Mean depth and coverage rate of all samples are summarized in Supplementary Table 3.

**Sequencing data analysis**
Fastq format files were generated by bcl2fastq software. Novoalign software (Novocraft Technologies, Kuala Lumpur, Malaysia) was used to align reads on the hg19/GRCh37 human reference genome sequence. Aligned reads were sorted by Novosort software (Novocraft) and subjected to the marking of PCR and optical duplication by MarkDuplicates in the Picard tools package (http://broadinstitute.github.io/picard/). The Genome Analysis Toolkit (GATK) was used to perform local realignment (GATK IndelRealigner) and variant call (GATK HaplotypeCaller) was implemented in an in-house workflow management tool. Single nucleotide variations (SNVs) and insertions/deletions (indels) were annotated using ANNOVAR software. Substitutions that met the following criteria were selected as “deleterious”: (1) mutations: lead stop gain, stop loss, nonsynonymous, or splice site mutations according to GENCODE basic version 19 downloaded from the UCSC genome browser; (2) alternative allele frequencies at mutation loci ≤0.5% in the following databases: 1000 Genomes Project data on all populations released in October 2014; NIH NHLBI 6515 exome data (http://evs.gs.washington.edu/EVS/); Exome Aggregation Consortium (ExAC) 65000 exome data; Human Genomic Variation Database (HGVD) exome data of 1208 individuals collected in Japan; SNV allele frequency collected from whole-genome sequencing data of 2049 healthy Japanese individuals (2KJPN) (https://ijgvd.megabank.tohoku.ac.jp); and (3) mutations not included in the UCSC segmental duplication region.

**Sanger sequencing**
We performed Sanger sequencing to confirm 127 variants shared among two affected individuals (II-1 and II-12) but absent from an unaffected one (I-2), which emerged from the WES. All primers were designed using Primer3. Genomic DNA (5 ng) was amplified using KOD FX Neo polymerase (Toyobo, Osaka, Japan) by PCR in 20-μl reactions. PCR mixtures were subjected to the following thermal cycling conditions: initial denaturation at 94 °C for 2 min; 32 cycles of denaturation at 98 °C for 10 s, annealing at 60 °C for 15 s, and extension at 68 °C for 30 s; and then final extension at 68 °C for 5 min. The PCR products were purified with AMPureXP (Agencourt, Beverly, MA, USA) and sequencing reactions were performed using the BigDye Terminator Cycle Sequencing Kit v3.1 (Applied Biosystems, Foster City, CA, USA), in accordance with the manufacturer’s instructions. After purification using CleanSEQ (Agencourt), the PCR products were separated and run on an ABI Genetic Analyzer 3130 (Applied Biosystems) and the electropherograms were evaluated using 4Peaks software (http://nucleoobies.com/4peaks/). Ten SNVs/indels were detected in all five affected family members. The original ten variants are summarized in Table 1.

**Linkage and haplotype analysis of candidate variants**
We performed linkage analysis of ten potential candidate variants using the MLINK program of the LINKAGE/FASTLINK software package (https://www.ncbi.nlm.nih.gov/CCBresearch/Schaffer/fastlink.html) assuming a dominant model. The parameter of the penetrance ratio was varied depending on each phenotype/genotype rate in this family (Table 1).
Mutational analysis of all exons among seven genes

We sequenced all exons of the seven genes (*ADRA1D*, *ATP8B4*, *C10orf120*, *GANC*, *GFRA4*, *HDHD3*, and *PLA2G4E*) identified by the above procedure in 573 samples (381 Japanese patients with PD; 96 German patients with PD; 96 German controls) by amplicon sequencing. WES in-house data on 571 Japanese individuals from another project were also used. Primers were designed using Ion Ampliseq Designer (https://www.ampliseq.com/browse.action) (Supplementary Table 4). In amplicon sequencing, all exons within these seven genes were amplified using KAPA2G Multiplex PCR Kit (KAPA Biosystems, Woburn, MA, USA) or KOD Extreme Hot-Start Polymerase (Toyobo, Osaka, Japan) by PCR. The samples were subjected to the following thermal conditions: initial denaturation at 95 °C for 2 min; and then 25 cycles of denaturation at 95 °C for 30 s, annealing at 60 °C for 120 s, and extension at 72 °C for 120 s. PCR amplicons were sonicated to a size of 180 bp using Covaris E220 (Covaris, Woburn, MA, USA). End-repair, A-tailing, and adapter ligation were performed in accordance with the manufacturer’s protocol for KAPA HTP Library Preparation Kits for Illumina Platforms. After adapter ligation, the samples were amplified using KAPA HiFi HotStart Ready Mix (KAPA Biosystems, Wilmington, MA, USA) by PCR with indexed primers. Samples were subjected to the following thermal cycling conditions: initial denaturation at 98 °C for 45 s; seven cycles of denaturation at 98 °C for 15 s, annealing at 60 °C for 30 s, and extension at 72 °C for 30 s; and final extension at 72 °C for 1 min. Prepared amplicon libraries were sequenced using HiSeq 2500 (Illumina). The mean depth of all samples is summarized in Supplementary Table 5.

Single-variant association test

To detect the single variants associated with PD, we used PLINK18 to estimate p value and odds ratios. In this study, we filtered out the variants using the following criteria: alternative allele frequencies of less than 0.005 in the samples in this study, exact test of Hardy–Weinberg equilibrium: \( p < 1 \times 10^{-6} \), and call rates of less than 90%. In total, 16 and 19 variants were found in the Japanese and Germans, respectively, so the significant thresholds of p values were set to 0.0031 in the Japanese and 0.0026 in the Germans, in accordance with Bonferroni correction.

Gene-based rare variant association tests

To test differences in the mutational burden of the candidate genes, we used Efficient and Parallelizable Association Container Toolbox (EPACTS). In the EPACTS algorithms, we used three different analyses (CMC19, Madsen–Browning20, and SKAT-O21). We removed common variants using the following criteria: alternative allele frequency of more than 0.005 in any...
public database (ExAC, ESP6500, 1000 Genomes, HGVD, and ToMMo 2KJPN) or more than 0.005 in control samples in this study; call rate of less than 90% in the study samples; and genotyping quality score of less than 99. In German samples, GFRA4 was removed from the analysis because of the lack of a variant allele. The significance threshold here was set to 0.0167, in accordance with Bonferroni correction.

Results

Segregation analysis
The segregation analysis using SAGE algorithms showed that the “Mendelian major gene models with autosomal-dominant inheritance,” which was the plausible mode of inheritance in this family. This result indicated that this family carries a single locus with a strong impact on PD. The AIC scores are summarized in Supplementary Table 6.

Linkage analysis
Two-point logarithm of the odd (LOD) scores were calculated by FASTLINK software. The LOD scores of ten variants are summarized in Table 1.

Whole-exome sequencing and Sanger sequencing
We identified 127 functionally significant variants shared by the two affected individuals subjected to WES. To identify compelling candidates, we searched variants shared among all affected members by Sanger sequencing of these 127 variants (Fig. 1). As a result, nine SNVs and one deletion were found in all affected members (Table 1).

Mutational screening of seven familial substitutions in Japanese and German PD case–control groups
To examine the allele frequencies of these candidate alterations, we screened these substitutions in Japanese and Germans with or without PD (Supplementary Table 2). In the Japanese (384 patients with PD and 571 matched controls), we found some SNVs that had been identified in the WES (chr20: 4202670, G>A in ADRA1D; chr15: 50271864, C>T in ATP8B4; chr10: 124459278, T>C in C10orf120; chr9: 116136256, G>- in HDHD3). These four variants were also observed in controls. Furthermore, none of these variants showed a significant preponderance in PD cases relative to the level in controls, so they were considered to be polymorphisms that did not have a major role in the development of PD. However, three SNVs (chr15: 42631993, T>C in GANC; chr15: 42342861, G>T in PLA2G4E; chr20: 3641457, G>C in GFRA4) were “novel variants,” since they were not observed in controls or in any databases and their allele frequencies and estimated pathogenic impact could not be evaluated (Table 2). Taking these findings together, we considered these three SNVs to be potential pathogenic variants in this family (Table 2). In contrast, in the Germans (288 patients and 288 controls), none of these seven variants was found in either patients or controls.

Gene-based rare variant association tests
To examine whether there was an excess of rare mutations resulting in protein alterations of three genes (GANC, GFRA4, and PLA2G4E) in patients with PD compared with their levels in controls, we performed gene-based rare variant association tests using EPACTS algorithms. In the Japanese group (384 patients and 571 controls), PLA2G4E showed the lowest p values (p = 0.0715 in CMC, p = 0.0658 in Madsen–Browning,
Morimoto et al. Translational Psychiatry (2018) 8:41
Page 6 of 8

Table 3 Results of single-variant association tests

| Variants | Mutation allele counts | P value | OR |
|----------|------------------------|---------|----|
| Japan gene PD (N = 762) | Control (N = 1142) |
| PLA2G4E chr15: 42298189; C>T | 12 | 7 | 0.06299 | 2.434 |
| GFRA4 chr20: 3640641; A>G | 12 | 8 | 0.069 | 2.3 |
| GANC chr15: 42643538; G>A | 53 | 60 | 0.1659 | 1.329 |
| GANC chr15: 42579984; A>G | 52 | 60 | 0.197 | 1.299 |
| PLA2G4E chr15: 42292389; A>G | 2 | 8 | 0.2098 | 0.3507 |
| Germany gene PD (N = 192) | Control (N = 192) |
| GANC chr15: 42619508; C>T | 15 | 25 | 0.09344 | 0.539 |
| GFRA4 chr20: 3640823; C>T | 96 | 75 | 0.0971 | 1.427 |
| GFRA4 chr20: 3644082; T>C | 1 | 5 | 0.1168 | 0.1895 |
| GANC chr15: 42579984; A>G | 17 | 9 | 0.1543 | 1.933 |
| GANC chr15: 42631928; C>T | 17 | 24 | 0.1892 | 0.6387 |

Top five loci are displayed with the lowest p value first. The significance thresholds were as follows: Japan, 0.0031; and Germany, 0.0026.

Table 4 Results of gene-based rare variant association tests

| Number of markers | P value CMC | Madsen–Browning | SKAT-O |
|-------------------|-------------|-----------------|--------|
| Japanese gene     |             |                 |        |
| GANC              | 6           | 0.9977          | 0.9939 | 0.5172 |
| GFRA4             | 3           | 0.9744          | 0.1026 | 0.1699 |
| PLA2G4E           | 12          | 0.0715          | 0.0658 | 0.1624 |
| Germany gene      |             |                 |        |
| GANC              | 5           | 0.2751          | 0.2645 | 0.415  |
| PLA2G4E           | 6           | 0.0652          | 0.0347 | 0.0646 |

The significance threshold was set to 0.0167.

0.1624 in SKAT-O), but did not reach the significance threshold. PLA2G4E also showed the lowest p values (p = 0.0652 in CMC, p = 0.0347 in Madsen–Browning, p = 0.0646 in SKAT-O) in the German population (Table 4 and Supplementary Tables 9 and 10).

Discussion

In this study, we focused on rare protein-altering variants in a Japanese family, including multiple patients, with PD to identify genetic variants contributing to the risk of this disorder. Recent studies have indicated that the genetic risk of psychiatric disorders involves the combined effects of many common variants of small effect, as well as rare variants of large effect including gene-disrupting mutations that might have a strong impact on the development of diseases.22–24. They have also suggested the possibility that an extremely large effect of even just a single variant could cause diseases. In the present study, we hypothesized that there may be rare highly penetrant mutations with a very large effect in this family; this was supported by the findings of affected individuals through three generations and the autosomal-dominant inheritance mode identified from the segregation analysis. Assuming that the penetrance of the rare mutation was going to be high with incomplete penetrance, there is a possibility that the siblings of the proband were inherited the rare mutation with a large effect. First, for primary candidates, we selected variants that all affected individuals carried but that the father of the proband did not carry from the results of both WES and Sanger sequencing, resulting in ten variants remaining. Subsequently, we eliminated four of these seven candidate variants since none of them showed significant accumulations in PD from the results of sequencing of our case–control group, despite each allele frequency being less than 0.003 in a public database.

The significance threshold was set to 0.0167.

0.1624 in SKAT-O), but did not reach the significance threshold. PLA2G4E also showed the lowest p values (p = 0.0652 in CMC, p = 0.0347 in Madsen–Browning, p = 0.0646 in SKAT-O) in the German population (Table 4 and Supplementary Tables 9 and 10).

Discussion

In this study, we focused on rare protein-altering variants in a Japanese family, including multiple patients, with PD to identify genetic variants contributing to the risk of this disorder. Recent studies have indicated that the genetic risk of psychiatric disorders involves the combined effects of many common variants of small effect, as well as rare variants of large effect including gene-disrupting mutations that might have a strong impact on the development of diseases.22–24. They have
Seven variants were thus eliminated from the primary ten candidates because they were assumed to have very low penetrance. Recent studies have also suggested that minor allele frequencies have a strong association with their odds ratios22,23, which supported our filtering strategy. As a result of this filtering, we identified three rare protein-altering variants as potential disease-causing candidates after resequencing and filtering. We then performed mutational burden analyses of these three potential candidate genes. A single-variant association test of these three potential candidates did not show any association with PD. Because association testing using common single variants is effective for detecting loci with small phenotypic effects26, GWAS is a suitable method to detect common loci associated with complex diseases including psychiatric conditions27,28. GWAS focusing on PD has already been reported in the Japanese and German populations, which identified several candidate genes (e.g., TMEM132D, PKP1, PLEKHG1, and CLU)6,29, although these do not overlap with the three candidate genes identified in the present study. In gene-based rare variant association tests, PLA2G4E showed the lowest p value among the three candidates in this study, but did not reach the significance threshold in either the Japanese or the German group. There are several possible explanations for this. First, the significance threshold after Bonferroni correction might be too stringent to achieve the precise detection of meaningful variants in gene-based rare variant methods. Recent studies have indicated that existing gene-based rare variant methods might not be able to detect disease-related variants at the exome-wide significance threshold despite the effect size of variants being relatively large30–32. They also suggested that the absence of a positive signal in gene-based association studies does not exclude a role of rare variation in diseases. The second possibility is that the effect size of variants is not so large. Moutsianas et al. demonstrated that the power of detection in gene-based association tests is inversely related to the degree of linkage disequilibrium between causal variants at a locus30. The effect size of three potential candidates might have influenced to our negative results. The last possible explanation is that the sample size was too small. To boost the statistical power of the gene-based rare variant association method, it is usually necessary to increase the sample size30–32. A small sample size is thus one of the limitations of our study.

To the best of our knowledge, no study has yet reported an association between PLA2G4E and PD. PLA2G4E is very poorly characterized, although a few studies have revealed its functions. For example, Ohno et al. demonstrated that recombinant PLA2G4E influences phospholipase activity34, while Ogura et al. showed that it is strongly expressed in the brain, especially in neurons, and regulates bioactive lipids, namely, N-acyl phosphatidylethanolamines and N-acyl ethanolamines including the endocannabinoid anandamide, by mobilizing intracellular calcium in mammalian cells35. They also surmised that the PLA2G4E-regulated pathway might provide new therapeutic strategies for neuropsychiatric diseases. Interestingly, in recent years, a number of studies have presented evidence for the involvement of the endocannabinoid system (ECS) in PD36,37. The cannabinoid type 1 receptors influence the glutamatergic and GABAergic regulation of anxiety and fear response, which can be recognized as a key regulatory element in the pathogenesis of PD38. However, functional analyses of variants of PLA2G4E have yet to be performed, which are needed to draw definitive conclusions on the causal association between these variants in PLA2G4E and ECS/neurotransmitter release.

In conclusion, we failed to identify any genes responsible for the development of PD through exome sequencing in a Japanese family featuring multiple patients with PD as well as through a case–control study. PLA2G4E showed the lowest p value among the three candidates in this study in both of the two different ethnic groups; however, none of the genes or variants reached the threshold for statistical significance. Nonetheless, considering both our genetic findings and protein functions, the possibility remains that PLA2G4E could be involved in the pathogenesis of PD and become a new therapeutic target for this disorder.

Acknowledgements

We thank the members of the family for participating in this study. We also thank Chisa Hayashida for technical support with the NGS. This work was supported in part by a grant from Senshin Medical Research Foundation (S.O.); the Initiative on Rare Undiagnosed Diseases in Pediatrics (IRUD-P) project (K.Y.), and the Practical Research Project for Rare/Intractable Diseases from the Agency for Medical Research and Development; Grants-in-Aid for Scientific Research (B) (K.Y.) and (C) (A.K. and S.O.) from the Japan Society for the Promotion of Science; and Takeda Scientific Foundation (K.Y.). We also thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Author details

1 Department of Neuropsychiatry, Unit of Translation Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 2 Department of Human Genetics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 3 Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 4 Graduate School of Clinical Psychology, Professional Degree Program in Clinical Psychology, Teikyo Heisei University, Tokyo, Japan. 5 Arata-clinic, Nagasaki, Japan. 6 Department of Psychiatry, Psychosomatics, and Psychotherapy, Center of Mental Health, University of Würzburg, Würzburg, Germany. 7 Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 8 Division for Environment, Health and Safety, The University of Tokyo, Tokyo, Japan. 9 Department of Neuropsychiatry, Teikyo University School of Medicine, Tokyo, Japan. 10 Panic Disorder Research Center, Warakukai Med. Corp, Tokyo, Japan. 11 Department of Psychiatry, Koselkai Michino-o Hospital, Nagasaki, Japan. 12 Department of Physical and Health Education, Graduate School of Education, The University of Tokyo, Tokyo, Japan. 13 Aino-Ariake Hospital, Unzen, Nagasaki, Japan.

Translational Psychiatry (2018) 8:41
Author contributions
Conception and design of the study: S.O. and K.-I.Y. Analysis and interpretation of data: Y.M., M.S.-S., T.O., S.Y., A.K., H.M., N.Y., T.M., A.I., H.O., N.K., C.Z., K.D., J.D., T. U., M.T., H.K., Y.O., K.T., S.S., S.O., and K.-I.Y. Manuscript preparation: Y.M. and S.O.

Conflict of interest
The authors declare that they have no conflict of interest.

Ethics regarding human subjects
Experimental procedures were approved by the Committee for the Ethical Issues on Human Genome and Gene Analysis at Nagasaki University. The methods were carried out in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41398-017-0088-0.

Received: 13 July 2017 Revised: 9 November 2017 Accepted: 30 November 2017
Published online: 02 February 2018

References
1. Kessler, R. et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry 55, 801–808 (1998).
2. Goldstein, R. B., Wickramaratne, P. J., Horwath, E. & Weissman, M. Familial aggregation and phenomenology of early-onset (at or before age 20 years) panic disorder. Arch Gen Psychiatry 54, 271–278 (1997).
3. Hettema, J. M., Neale, M. C. & Kendler, K. S. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 158, 1568–1578 (2001).
4. Gelernter, J. et al. Linkage genome scan for loci predisposing to panic disorder or agoraphobia. Am J Med Genet 105, 548–557 (2001).
5. Fyer, A. J. et al. A third-pass genome scan in panic disorder: evidence for multiple susceptibility loci. Biol Psychiatry 60, 388–401 (2006).
6. Otowa, T. et al. Replication of a genome-wide association study of panic disorder in a Japanese population. J Hum Genet 55, 91–96 (2010).
7. Helmsmoortel, C. et al. A SW/SNF-related autism syndrome caused by de novo mutations in ARID1B. Nat Genet 46, 380–384 (2014).
8. Gregersen, N. O. et al. Whole-exome sequencing implicates DGKH as a risk gene for panic disorder in the Faroese population. Am J Med Genet B 171, 1013–1022 (2016).
9. Faqeih, E. A. et al. Novel homozygous DEAF1 variant suspected in causing white matter disease, intellectual disability, and microcephaly. Am J Med Genet A 164, 1565–1570 (2014).
10. Wang, Z., Liu, X., Yang, B. Z. & Gelernter, J. The role and challenges of exome sequencing in studies of human diseases. Front Genet 6, 160 (2013).
11. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297–1303 (2010).
12. Mishra, H., Sasaki, K., Tanaka, M., Tatebe, O. & Yoshiura, K. Agile parallel bioinformatics workflow management using Pwvake. BMC Res Notes 4, 331–338 (2011).
13. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from next-generation sequencing data. Nucleic Acids Res 38, e164 (2010).
14. 1000 Genomes Projects Consortium, Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
15. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
16. Higasa, K. et al. Human genetic variation database, a reference database of genetic variations in Japanese population. J Hum Genet 61, 547–553 (2016).
17. Rozen, S. & Skaltsky, H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132, 365–386 (2000).
18. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559–575 (2007).
19. Li, B. & Leal, S. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 83, 311–321 (2008).
20. Madsen, B. E. & Browning, S. R. A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet 5, e1000384 (2009).
21. Lee, S. et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am J Hum Genet 91, 224–237 (2012).
22. Gratten, J., Wray, N. R., Keller, M. C. & Visscher, P. M. Large-scale genomics unveils the genetic architecture of psychiatric disorders. Nat Neurosci 17, 782–790 (2014).
23. Iossifov, I. et al. De novo gene disruptions in children on the autistic spectrum. Neuron 74, 285–299 (2012).
24. Sanders, S. J. et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485, 237–241 (2012).
25. Reddy, M. A. et al. A clinical and molecular genetic study of a rare dominantly inherited syndrome (MRCs) comprising of microcornea, rod-cone dystrophy, cataract, and posterior staphyloma. Br J Ophthalmol 87, 197–202 (2003).
26. Kazun, A. et al. Exome sequencing and the genetic bases of complex traits. Nat Genet 44, 623–630 (2012).
27. Manolio, T. A. Genome-wide association studies and assessment of risk of disease. N Engl J Med 363, 166–176 (2010).
28. Gelernter, J. Genetics of complex traits in psychiatry. Biol Psychiatry 77, 36–42 (2015).
29. Erhardt, A. et al. TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry 16, 647–663 (2011).
30. Moutsianas, L. et al. The power of gene-based rare variant methods to detect disease-associated variation and test hypotheses about complex disease. PLoS Genet 11, e1005165 (2015).
31. Guo, M. H. et al. Determinants of power in gene-based burden testing for monogenic disorders. Am J Hum Genet 99, 527–539 (2016).
32. Sham, P. C. & Purcell, S. M. Statistical power and significance testing in large-scale genetic studies. Nat Rev Genet 15, 335–346 (2014).
33. Wang, M., Ma W. & Zhou Y. Association detection between ordinal trait and rare variants based on adaptive combination of P values. J Hum Genet 61, 194–202 (2016).
34. Ohto, T., Uozumi, N., Hirabayashi, T. & Shimizu, T. Identification of novel cytosolic phosphophospholipid A2/2, murine cPLA(2)[delta,epsilon], and [zeta], which form a gene cluster with cPLA2( beta). J Biol Chem 280, 24576–24583 (2005).
35. Ogura, Y., Parsons, W. H., Kamat, S. S. & Cravatt, B. F. A calcium-dependent acyltransferase that produces N-acyl phosphatidylethanolamines. Nat Chem Biol 12, 668–671 (2016).
36. Batista, L. A., Basto, J. R. & Moreira, F. A. Role of endocannabinoid signaling in the dorsolateral periaqueductal grey in the modulation of distinct panic-like responses. J Psychopharmacol 29, 334–343 (2015).
37. Viana, T. G., Hott, S. C., Reisll, L. B., Aguiar, D. C. & Moreira, F. A. Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attack in rats. Psychopharmacology 232, 1455–1533 (2015).
38. Ruehle, S., Ray, A. A., Remmers, F. & Lutz, B. The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol 26, 23–39 (2012).